RESUMO
In 2013, the National Safety Council's Alcohol Drugs and Impairment Division added zolpidem and carisoprodol and its metabolite meprobamate to the list of Tier 1 drugs that should be tested for in all suspected drug impaired driving and motor vehicle fatality investigations. We describe the validation of an enzyme linked immunosorbent assays (ELISA) for both drugs in whole blood, and the utilization of the ELISA to assess their positivity in a sample of 322 suspected impaired driving cases that was retrospectively screened using the validated assays. The occurrence of carisoprodol/meprobamate was found to be 1.2%, and for zolpidem, 1.6%. In addition, we analyzed a large dataset (n = 1,672) of Driving Under the Influence of Drugs (DUID) test results from a laboratory performing high volume DUID testing to assess the frequency of detection of both drugs after implementing the expanded NSC scope. Carisoprodol or meprobamate were found positive in 5.9% (n = 99) of these samples, while zolpidem was found positive in 5.3% (n = 89) in drivers who in many cases had been found to be negative for other drugs. Carisoprodol and zolpidem are both potent CNS depressants and are appropriate additions to the recommended NSC scope of testing.
Assuntos
Condução de Veículo , Carisoprodol/sangue , Depressores do Sistema Nervoso Central/sangue , Dirigir sob a Influência/estatística & dados numéricos , Meprobamato/sangue , Piridinas/sangue , Detecção do Abuso de Substâncias , Dirigir sob a Influência/legislação & jurisprudência , Ensaio de Imunoadsorção Enzimática , Regulamentação Governamental , Humanos , Estudos Retrospectivos , Detecção do Abuso de Substâncias/legislação & jurisprudência , Detecção do Abuso de Substâncias/métodos , Detecção do Abuso de Substâncias/estatística & dados numéricos , Estados Unidos , ZolpidemRESUMO
Carisoprodol and meprobamate are centrally acting muscle relaxant/anxiolytic drugs that can exist in a parent-metabolite relationship (carisoprodol â meprobamate) or as a separate pharmaceutical preparation (meprobamate aka Equanil, others). The monitoring of the use of these drugs has both clinical and forensic applications in pain management applications and in overdose situations. LC-MS/MS is used to analyze urine or plasma/serum extracts with deuterated analogs of each analyte as internal standards to ensure accurate quantitation and control for any potential matrix effects. Positive ion electrospray is used to introduce the analytes into the mass spectrometer. Selected reaction monitoring of two product ions for each analyte allows for the calculation of ion ratios which ensures correct identification of each analyte, while a matrix-matched calibration curve is used for quantitation.
Assuntos
Carisoprodol/sangue , Carisoprodol/urina , Meprobamato/sangue , Meprobamato/urina , Relaxantes Musculares Centrais/sangue , Relaxantes Musculares Centrais/urina , Espectrometria de Massas em Tandem/métodos , Cromatografia Líquida/métodos , HumanosRESUMO
A multidrug fatality involving sumatriptan is reported. Sumatriptan is a tryptamine derivative that acts at 5-HT(1B/1D) receptors and is used for the treatment of migraines. The decedent was a 21-year-old white female found dead in bed by her spouse. No signs of physical trauma were observed and a large number of prescription medications were discovered at the scene. Toxicological analysis of the central blood revealed sumatriptan at a concentration of 1.03 mg/L. Following therapeutic dosing guidelines, sumatriptan concentrations do not exceed 0.095 mg/L. Sumatriptan was isolated by solid-phase extraction and analyzed using liquid chromatography-tandem mass spectrometry in multiple reaction monitoring mode. A tissue distribution study was completed with the following concentrations measured: 0.61 mg/L in femoral blood, 0.56 mg/L in iliac blood, 5.01 mg/L in urine, 0.51 mg/kg in liver, 3.66 mg/kg in kidney, 0.09 mg/kg in heart, 0.32 mg/kg in spleen, 0.01 mg/kg in brain, 15.99 mg/kg in lung and 78.54 mg/45 mL in the stomach contents. Carisoprodol, meprobamate, fluoxetine, doxylamine, orphenadrine, dextromethorphan and hydroxyzine were also present in the blood at the following concentrations: 3.35, 2.36, 0.63, 0.19, 0.06, 0.55 and 0.16 mg/L. The medical examiner ruled the cause of death as acute mixed drug toxicity and the manner of death as accident.
Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/sangue , Sumatriptana/intoxicação , Autopsia , Carisoprodol/sangue , Cromatografia Líquida , Dextrometorfano/sangue , Doxilamina/sangue , Estudos de Avaliação como Assunto , Evolução Fatal , Feminino , Fluoxetina/sangue , Toxicologia Forense , Humanos , Hidroxizina/sangue , Fígado/efeitos dos fármacos , Fígado/metabolismo , Meprobamato/sangue , Orfenadrina/sangue , Reprodutibilidade dos Testes , Manejo de Espécimes , Sumatriptana/farmacocinética , Espectrometria de Massas em Tandem , Distribuição Tecidual , Adulto JovemRESUMO
The identification and quantitation of carisoprodol (Soma) and its chief metabolite meprobamate, which is also a clinically prescribed drug, remains a challenge for forensic toxicology laboratories. Carisoprodol and meprobamate are notable for their widespread use as muscle relaxants and their frequent identification in the blood of impaired drivers. Routine screening is possible in both an acidic/neutral pH screen and a traditional basic screen. An improvement in directed testing quantitations was desirable over the current options of an underivatized acidic/neutral extraction or a basic screen, neither of which used ideal internal standards. A new method was developed that utilized a simple protein precipitation, deuterated internal standards and a short 2-min isocratic liquid chromatography separation, followed by multiple reaction monitoring with tandem mass spectrometry. The linear quantitative range for carisoprodol was determined to be 1-35mg/L and for meprobamate was 0.5-50mg/L. The method was validated for specificity and selectivity, matrix effects, and accuracy and precision.
Assuntos
Carisoprodol/sangue , Cromatografia Líquida de Alta Pressão/métodos , Meprobamato/sangue , Espectrometria de Massas em Tandem/métodos , Carisoprodol/química , Estabilidade de Medicamentos , Feminino , Toxicologia Forense/métodos , Humanos , Modelos Lineares , Meprobamato/química , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Detecção do Abuso de Substâncias/métodosRESUMO
INTRODUCTION: Carisoprodol, a frequently used muscle relaxant, can cause potentially fatal intoxications. Conversion to its active metabolite meprobamate is almost solely mediated by cytochrome P450 2C19 (CYP2C19), and mutations in this enzyme could have significant effects on serum concentrations. The objective of this study was to investigate the role of CYP2C19 genetics in mortalities due to carisoprodol intoxication. METHODS: The frequencies of CYP2C19 variant alleles were compared between the study group (n = 75) and two control groups, i.e. (1) deaths where carisoprodol was detected in the blood of the deceased, but intoxication was not the cause of death (control group A, n = 38), and (2) a healthy population not using carisoprodol (control group B, n = 185). In the study group and control A, the concentrations of carisoprodol and meprobamate were compared between the different genotype subgroups. RESULTS: The variant allele frequencies of CYP2C19 did not differ significantly between the study group and control groups. Moreover, no statistically significant difference in the concentrations of carisoprodol and meprobamate between the different genotype subgroups was found. CONCLUSIONS: This study finds no evidence for an important association between CYP2C19 genetics and mortality risk of carisoprodol. Other factors, such as co-administration with other drugs, likely play a more important role.
Assuntos
Hidrocarboneto de Aril Hidroxilases/genética , Carisoprodol/intoxicação , Relaxantes Musculares Centrais/intoxicação , Polimorfismo Genético , Alelos , Hidrocarboneto de Aril Hidroxilases/metabolismo , Autopsia , Biotransformação , Carisoprodol/sangue , Carisoprodol/farmacocinética , Causas de Morte , Citocromo P-450 CYP2C19 , Frequência do Gene , Estudos de Associação Genética , Humanos , Meprobamato/sangue , Relaxantes Musculares Centrais/sangue , Relaxantes Musculares Centrais/farmacocinética , Noruega/epidemiologia , RiscoRESUMO
Carisoprodol is a therapeutic and occasionally abused centrally acting muscle relaxant. We compare central blood and liver concentrations of carisoprodol and the metabolite meprobamate to concentrations in peripheral blood in 11 medical examiner cases. Specimens were initially screened for alcohol and simple volatiles by gas chromatography (GC)-flame ionization detection headspace analysis, enzyme-linked immunosorbent array for drugs of abuse, and therapeutic drugs by GC-mass spectrometry (MS). Carisoprodol, when detected by the therapeutic drug screen, was confirmed and quantified by a specific GC-MS procedure. The results suggest that when ingested with other medications, carisoprodol may be a contributing factor in death, even when present at therapeutic concentrations. Considering the cases studied, together with previously published therapeutic and fatal concentrations, blood carisoprodol concentrations greater than 15 mg/L and liver concentrations greater than 50 mg/kg may be considered excessive and potentially fatal. Carisoprodol central blood to peripheral blood ratios averaged 1.31 + 0.33 (mean ± standard deviation), and liver to peripheral blood, 2.83 ± 1.51. Meprobamate central blood to peripheral blood ratios averaged 0.92 ± 0.22, and liver to peripheral blood, 1.25 ± 0.69. The low liver to peripheral blood ratio (less than 5), taken together with the low central blood to peripheral blood ratio, is an indicator that both carisoprodol and meprobamate lack the potential to exhibit postmortem redistribution.
Assuntos
Carisoprodol/intoxicação , Meprobamato/intoxicação , Relaxantes Musculares Centrais/intoxicação , Detecção do Abuso de Substâncias/métodos , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Carisoprodol/sangue , Carisoprodol/farmacocinética , Diagnóstico , Toxicologia Forense/métodos , Cromatografia Gasosa-Espectrometria de Massas , Humanos , Fígado/metabolismo , Meprobamato/sangue , Meprobamato/farmacocinética , Relaxantes Musculares Centrais/sangue , Relaxantes Musculares Centrais/farmacocinética , Mudanças Depois da Morte , Transtornos Relacionados ao Uso de Substâncias/sangue , Suicídio , Distribuição TecidualRESUMO
BACKGROUND: Meprobamate is a carbamate, and the main metabolite of carisoprodol. It is used as an anxiolytic agent. Overdose of both drugs produces intoxication that is often serious and sometimes life threatening. However there was until now no immunoassay for the diagnosis of this intoxication. METHODS: A chemiluminescent immunoassay for the semi-quantitative measurement of meprobamate in human blood and plasma has recently been developed, using the Evidence Investigator system (Randox®). In this study, the immunoassay was evaluated by testing drug-free (n=10) or spiked whole blood and plasma samples (n=70), and authentic post mortem whole blood samples from deceased patients in which meprobamate was present (n=38) or not (n=10). A previously validated gas chromatography-mass spectrometry (GC-MS) method was used for confirmation and quantification. 97 psychoactive drugs including carisoprodol were analyzed for possible interference. RESULTS: With a cut-off at 0.5 mg/L, specificity, sensitivity and accuracy were 100%, 97.2% and 97.6%, respectively. All the untreated patients presented results under the cut-off. Meprobamate was not detected in three whole blood samples spiked with concentrations under the therapeutic range. In the authentic patients (n=48), there were no false-negative results. A good correlation was found between the immunoassay and GC-MS (r=0.90). Quantitative results of the immunoassay are approximately two-fold lower than GC-MS results. Only carisoprodol presented a cross-reactivity, 38±6.6% at 10 mg/L, and 26±4.8% at 100mg/L. CONCLUSION: The first meprobamate immunoassay has shown very good specificity, selectivity and accuracy, which allow its use in hospital clinical laboratories for rapid diagnosis of meprobamate (or carisoprodol) intoxications.
Assuntos
Ansiolíticos/sangue , Imunoensaio/métodos , Dispositivos Lab-On-A-Chip , Meprobamato/sangue , Cromatografia Gasosa-Espectrometria de Massas , Humanos , Limite de Detecção , Luminescência , Reprodutibilidade dos TestesRESUMO
We described the development and full validation of rapid and accurate liquid chromatography method, coupled with tandem mass spectrometry detection, for quantification of meprobamate in human plasma with [(13)C-(2)H(3)]-meprobamate as internal standard. Plasma pretreatment involved a one-step protein precipitation with acetonitrile. Separation was performed by reversed-phase chromatography on a Luna MercuryMS C18 (20 mm×4 mm×3 µm) column using a gradient elution mode. The mobile phase was a mix of distilled water containing 0.1% formic acid and acetonitrile containing 0.1% formic acid. The selected reaction monitoring transitions, in electrospray positive ionization, used for quantification were 219.2â158.2 m/z and 223.1â161.1m/z for meprobamate and internal standard, respectively. Qualification transitions were 219.2â97.0 and 223.1â101.1 m/z for meprobamate and internal standard, respectively. The method was linear over the concentration range of 1-300 mg/L. The intra- and inter-day precision values were below 6.4% and accuracy was within 95.3% and 103.6% for all QC levels (5, 75 and 200 mg/L). The lower limit of quantification was 1 mg/L. Total analysis time was reduced to 6 min including sample preparation. The present method is successfully applied to 24/7 clinical toxicology and demonstrated its usefulness to detect meprobamate poisoning.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Meprobamato/sangue , Espectrometria de Massas em Tandem/métodos , Cromatografia de Fase Reversa , Humanos , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , ToxicologiaRESUMO
Clobazam is a benzodiazepine with anti-anxiety and anticonvulsant properties marketed in several countries. Norclobazam, a metabolite of clobazam, has similar pharmacological activity but weaker sedative and tranquilizing effect. The two drugs were detected by GC-MS and determined by HPLC-DAD in the samples from a postmortem case. The femoral blood concentrations of clobazam and norclobazam were 0.72 and 36 µg/mL, respectively. The concentration of the active norclobazam was very high. The sum of both clobazam and norclobazam blood concentration (36.72 µg/mL) was clearly toxic, but was not necessarily fatal. Other associated drugs concentrations were within their therapeutic ranges. Interactions due to drug association were discussed.
Assuntos
Anticonvulsivantes/sangue , Benzodiazepinas/sangue , Clorazepato Dipotássico/sangue , Meprobamato/sangue , Idoso , Anticonvulsivantes/intoxicação , Autopsia , Benzodiazepinas/intoxicação , Clobazam , Clorazepato Dipotássico/intoxicação , Overdose de Drogas , Evolução Fatal , Feminino , Humanos , Meprobamato/intoxicaçãoRESUMO
Carisoprodol and meprobamate are frequently encountered drugs in impaired driving casework. Deuterated internal standards, although preferred, were not available until recently. Earlier published studies report the use of a variety of non-deuterated internal standards, many of which lack the chemical and physical similarities that are desired for quantitative analysis. Carisoprodol and meprobamate were determined in whole blood using solid-phase extraction and gas chromatography-mass spectrometry with benzylcarbamate and meprobamate-d(7) as internal standards. When benzylcarbamate was used as internal standard, the linear ranges for carisoprodol and meprobamate were 0-20 mg/L and 0-40 mg/L, respectively. The linear range increased to 100 mg/L when meprobamate-d(7) was used. Limits of detection for carisoprodol and meprobamate were 0.2 and 0.4 mg/L, respectively, regardless of the internal standard selection. The limit of quantitation for both drugs using either internal standard was 0.4 mg/L. Accuracies using benzylcarbamate and meprobamate-d(7) were 100-106% and 91-100%, respectively. Corresponding values for precision indicated intra-assay coefficients of variation of 2.6-4.3% for benzylcarbamate and 1.0-2.3% for meprobamate-d(7). No carryover was evident at 100 mg/L, the highest concentration tested, and no interferences were observed. Results indicated that either benzylcarbamate or meprobamate-d(7) is a suitable internal standard for quantitative determination of carisoprodol or meprobamate from whole blood.
Assuntos
Carisoprodol/sangue , Meprobamato/sangue , Relaxantes Musculares Centrais/sangue , Animais , Carbamatos/sangue , Carisoprodol/química , Bovinos , Deutério/química , Medicina Legal/métodos , Cromatografia Gasosa-Espectrometria de Massas/métodos , Meprobamato/química , Relaxantes Musculares Centrais/química , Padrões de Referência , Reprodutibilidade dos Testes , Extração em Fase Sólida/métodos , Detecção do Abuso de Substâncias/métodosRESUMO
The centrally acting muscle relaxant carisoprodol has previously been shown to cause psychomotor impairment and to have a narrow therapeutic range. In Norway, carisoprodol was therefore reclassified to the highest scheduling level from 1 August 2007 and withdrawn from the market on 1 May 2008. The aim of this study was to examine to what extent this action resulted in reduced numbers of driving under the influence (DUI) cases and forensic autopsies concerning carisoprodol, as well as reduced numbers of contacts to the National Poisons Information Centre (NPIC) in Norway regarding carisoprodol. From 2004 to 2008, carisoprodol (and/or its metabolite meprobamate) was detected in a total of 1261 DUI cases, decreasing from 312 in 2004 to 47 in 2008. During the same period, carisoprodol was detected in 194 forensic autopsies, also here decreasing, from 53 cases in 2004 to 11 cases in 2008. The NPIC received 1180 contacts primarily concerning carisoprodol over this period, decreasing from 267 contacts in 2004 to 87 contacts in 2008. During the same period, the sales figures for carisoprodol decreased dramatically, and we observed a relation between the numbers of DUI cases, forensic autopsies and contacts to the NPIC concerning carisoprodol and the sales figures for the drug. This study showed that the rescheduling and withdrawal of carisoprodol from the Norwegian market had a positive effect on the prevalence of carisoprodol in impaired driving, deaths and contacts regarding intoxications. This, together with previous publications, indicates that the population reflected in our data uses regularly prescribed carisoprodol and, to a lesser degree, drug from an illegal street market.
Assuntos
Carisoprodol/intoxicação , Relaxantes Musculares Centrais/intoxicação , Retirada de Medicamento Baseada em Segurança , Acidentes de Trânsito , Condução de Veículo , Toxicologia Forense , Humanos , Meprobamato/sangue , Noruega/epidemiologia , Centros de Controle de Intoxicações , Intoxicação/epidemiologia , Intoxicação/mortalidade , Prevalência , Fatores de Risco , Detecção do Abuso de SubstânciasRESUMO
A rapid, sensitive, and ready-to-use gas chromatography-mass spectrometry method for meprobamate assay using carisoprodol as internal standard is described. The method involves extracting a 0.2-mL sample with chloroform, previously acidified with HCl 0.2N. For the quantitative analysis, we used selected-ion monitoring mode, selecting the ion m/z 144 for quantification of meprobamate and m/z 245 for carisoprodol. Excellent linearity was found between 0 and 200 mg/L plasma. The limit of detection was 0.58 mg/L, and the limit of quantification was 1.93 mg/L. A high reproducibility [intra-assay coefficient of variation (CV) range of 2.3-4.3% and interassay CV range of 5.5-12.3%] and accuracy (intra-assay range of 96.8-112.3% and interassay range of 85.5-99.3%) were observed. Recoveries were concentration-independent (87.0%, 76.2%, and 81.2% for 20, 75 and 150 mg/L, respectively). No interference from endogenous compounds, other metabolites of meprobamate, or frequently coadministered drugs was detected. This sensitive, simple assay for meprobamate in plasma, whole blood, and urine meets the current requirements for bioanalytical assays in overdose cases.
Assuntos
Meprobamato/sangue , Meprobamato/urina , Ansiolíticos/sangue , Ansiolíticos/urina , Bioensaio , Medicina de Emergência , Cromatografia Gasosa-Espectrometria de Massas , Humanos , Relaxantes Musculares Centrais/sangue , Relaxantes Musculares Centrais/urina , Plasma/químicaRESUMO
OBJECTIVE: Meprobamate self-poisoning has been reported as potentially inducing hypotension. We examined the incidence and causes of hypotension induced by this poisoning and its prognosis. DESIGN AND SETTING: Retrospective observational study conducted in a medical ICU between June 1997 and October 2003. Seventy-four patients admitted for meprobamate poisoning and needing mechanical ventilation were included. Demographic, clinical, and laboratory data were compared between patients with and without hypotension. All echocardiograms recorded in patients with hypotension were reviewed, and left ventricular (LV) and right ventricular (RV) functions were assessed. RESULTS: Twenty-nine (40%) patients exhibited hypotension without any significant difference in age, gender, cardiac history, or meprobamate concentration in blood when compared to patients without hypotension. Base excess was significantly lower in patients with hypotension. Echocardiography demonstrated a hypokinetic state, associating decreased LV ejection fraction (45+/-15%) and cardiac index (2+/-0.7 l min(-1) m(-2)), and increased inferior vena cava diameter. Most patients with hypotension received inotropic drugs by infusion, and were ventilated for significantly longer. CONCLUSIONS: Meprobamate self-poisoning induces hypotension, notably related to cardiac failure, in about 40% of cases. This has important therapeutic consequences, as frequent inotropic drug infusion. The mechanisms of cardiac toxicity remain largely unknown, and no predictive factor could be isolated.
Assuntos
Ansiolíticos/intoxicação , Hipotensão/induzido quimicamente , Meprobamato/intoxicação , Adulto , Ansiolíticos/sangue , Carvão Vegetal/uso terapêutico , Feminino , Esvaziamento Gástrico , Humanos , Incidência , Unidades de Terapia Intensiva , Masculino , Meprobamato/sangue , Pessoa de Meia-Idade , Prognóstico , Respiração Artificial , Estudos RetrospectivosRESUMO
RATIONALE: The active placebo hypothesis states that placebo effects are potentiated when an active drug is administered. OBJECTIVE: This hypothesis was tested in an experiment where information about the effect of a drug was combined with administration of an active drug or placebo. METHODS: Information that a drug acted as a relaxant, a stimulant, or as a placebo was crossed with oral administration of a relaxant drug (700 mg carisoprodol), a stimulant drug (400 mg caffeine) or placebo (lactose) in healthy volunteers ( n=94). Dependent variables were subjective and physiological measures of arousal, as well as serum carisoprodol and caffeine levels. Data were collected from 15 to 280 min after administration of drug or placebo. RESULTS: Caffeine increased alertness, systolic and diastolic blood pressure, startle blink reflexes, and skin conductance responses. Subjects were calmer after carisoprodol, and heart rate was increased. There was a positive correlation between increased arousal and carisoprodol levels when stimulant information had been provided. However, this was only seen when carisoprodol levels were very low. There was no evidence that caffeine modulated the placebo response. CONCLUSIONS: Active placebo responses were seen only transiently when carisoprodol levels were low, and only in the subjective arousal data. Caffeine did not support active placebo responses. The overall findings did not favour the active placebo hypothesis.
Assuntos
Estimulantes do Sistema Nervoso Central/farmacologia , Relaxantes Musculares Centrais/farmacologia , Adulto , Nível de Alerta/efeitos dos fármacos , Piscadela/efeitos dos fármacos , Pressão Sanguínea/efeitos dos fármacos , Cafeína/sangue , Cafeína/farmacologia , Carisoprodol/sangue , Carisoprodol/farmacologia , Catecolaminas/sangue , Estimulantes do Sistema Nervoso Central/sangue , Cromatografia Líquida de Alta Pressão , Relação Dose-Resposta a Droga , Eletromiografia , Feminino , Resposta Galvânica da Pele/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Hemodinâmica/efeitos dos fármacos , Humanos , Masculino , Meprobamato/sangue , Meprobamato/farmacologia , Relaxantes Musculares Centrais/sangue , Efeito Placebo , Reflexo/efeitos dos fármacos , Reflexo de Sobressalto/efeitos dos fármacosRESUMO
Our aim was to explore the agreement between clinically collected information on purported drug intake and plasma data in intentional drug overdose. We included all subjects with intentional drug overdose above 15 years of age consecutively admitted to the Emergency Department of the University Hospital during 4 months. Information about drugs used and sources of this information was collected and compared to presence of drug in plasma, concerning four drugs with high toxic potential (tricyclic antidepressants, meprobamate, paracetamol and ethanol). Sensitivity, specificity, predictive positive and negative values of all sources of information pooled were assessed for each drug. 413 intentional drug overdoses were included, 66% with more than one drug. According to clinical information, 8% took tricyclic antidepressants, 11% meprobamate, 9% paracetamol and 41% ethanol. Systematic plasma assays confirmed this in 59% of cases for tricyclic antidepressants, 76% for meprobamate and ethanol, and 77% for paracetamol. Plasma concentrations were considered toxic in 28% of cases for tricyclic antidepressants, 65% for meprobamate, 43% for ethanol and never for paracetamol. Tricyclic antidepressants and meprobamate were found unexpectedly in 3%, paracetamol in 7% and ethanol in 6%. Toxic concentrations were found only with meprobamate. The risk of erroneous, clinically collected information was greater by excess (25 to 40% false positives) than by lack (3 to 7% false negatives). Thus, the consequences of erroneous, clinically collected information were probably more excess cost for the institution than medical risk for the patients. However these results found at the population level may not be true at an individual level.
Assuntos
Acetaminofen/sangue , Antidepressivos Tricíclicos/sangue , Antidepressivos Tricíclicos/intoxicação , Meprobamato/sangue , Acetaminofen/intoxicação , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Overdose de Drogas/sangue , Overdose de Drogas/diagnóstico , Etanol/sangue , Etanol/intoxicação , Feminino , Hospitalização , Hospitais Universitários , Humanos , Pacientes Internados , Masculino , Meprobamato/intoxicação , Pessoa de Meia-Idade , Estudos Prospectivos , Inquéritos e QuestionáriosRESUMO
BACKGROUND: Carisoprodol is a centrally acting muscle relaxant commonly used for lower back pain. It is a drug of abuse and has been detected among impaired drivers. Carisoprodol's active metabolite meprobamate is thought to act through the GABA(A) receptor complex and produces a well-known impairing effect. It is unclear whether therapeutic intake of carisoprodol leads to impairment, and the effect of supratherapeutic doses has not been investigated. Possible impairment could further be a product of the parent drug and/or the metabolite meprobamate. The present study aimed to investigate if carisoprodol had an impairing effect by it self. METHODS: From the database at the Norwegian Institute of Public Health, Division for Forensic Toxicology and Drug Abuse 62 cases containing carisoprodol and meprobamate as only drugs were identified. These cases constituted our material. RESULTS: Impaired drivers (73%) had higher blood carisoprodol concentration than not impaired drivers (27%), but no difference in blood meprobamate concentration was found for all the drivers viewed together. Amongst occasional users of carisoprodol, however, there was difference in blood meprobamate concentration between not impaired and impaired drivers. The risk of being judged impaired rose with increasing blood carisoprodol concentration, but not with increasing blood meprobamate concentration. The clinical effects of carisoprodol as measured by the clinical test for impairment (CTI) resembled those of benzodiazepines with some important differences such as tachycardia, involuntary movements, hand tremor and horizontal gaze nystagmus, which may be specific carisoprodol effects. CONCLUSION: Carisoprodol probably has an impairing effect by itself, at least at blood concentration levels above which can be seen after therapeutic intake of the drug.
Assuntos
Condução de Veículo , Carisoprodol/efeitos adversos , Relaxantes Musculares Centrais/efeitos adversos , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Análise de Variância , Carisoprodol/sangue , Distribuição de Qui-Quadrado , Intervalos de Confiança , Humanos , Meprobamato/sangue , Relaxantes Musculares Centrais/administração & dosagem , Razão de Chances , Estatísticas não Paramétricas , Detecção do Abuso de Substâncias/métodos , Transtornos Relacionados ao Uso de Substâncias/sangueRESUMO
Carisoprodol is metabolized to meprobamate by the cytochrome P450 enzyme CYP2C19, encoded by the polymorphic CYP2C19 gene. Most studies on carisoprodol metabolism have been carried out on individuals phenotyped for CYP2C19 activity using the probe drug S-mephenytoin. We aimed to investigate whether the ratio of carisoprodol to meprobamate in a 'real life' setting could be predicted by CYP2C19 genotype or, more specifically, if high carisoprodol : meprobamate ratios in drugged drivers could be ascribed to the presence of mutant CYP2C19 alleles. From original material comprising 358 blood samples from apprehended drivers, two polarized groups were selected; a high-ratio group of 11 subjects where the carisoprodol : meprobamate ratio was >1 and a low-ratio control group of 23 subjects where the ratio was <0.31. Genotyping was carried out for the CYP2C19*2, CYP2C19*3 and CYP2C19*4 alleles. DNA samples from 94 healthy blood donors were used as reference material. The number of mutant alleles in the high-ratio and low-ratio groups was significantly higher and lower, respectively, than in the reference material. The increased number of mutant alleles in the high-ratio group was not due to the presence of many poor metabolizers, but to a high number of heterozygous individuals with the genotype CYP2C19*1/*2. This result indicates a gene dosage effect where the carisoprodol : meprobamate ratio reflects the number of active CYP2C19 alleles. The metabolism of carisoprodol to meprobamate is dependent on CYP2C19 genotype. Heterozygous individuals with the CYP2C19*1/*2 genotype have a reduced capacity for metabolizing carisoprodol, and should probably be regarded as intermediate metabolizers of this drug.
Assuntos
Hidrocarboneto de Aril Hidroxilases/genética , Hidrocarboneto de Aril Hidroxilases/metabolismo , Carisoprodol/metabolismo , Meprobamato/metabolismo , Oxigenases de Função Mista/genética , Oxigenases de Função Mista/metabolismo , Adulto , Alelos , Carisoprodol/sangue , Citocromo P-450 CYP2C19 , Feminino , Dosagem de Genes , Frequência do Gene , Genótipo , Heterozigoto , Humanos , Masculino , Meprobamato/sangue , Mutação , Projetos Piloto , Polimorfismo Genético , Valores de Referência , Estudos Retrospectivos , Transtornos Relacionados ao Uso de Substâncias/sangue , Transtornos Relacionados ao Uso de Substâncias/complicações , Transtornos Relacionados ao Uso de Substâncias/metabolismoRESUMO
Implementation of regulations to control the prescribing of benzodiazepines in New York State in 1989 resulted in a 55% decrease in benzodiazepine prescribing, with a concomitant increase in the rates of prescribing older sedative-hypnotic compounds such as butabarbital (30% increase) and meprobamate (125% increase). In a double-blind, crossover, placebo-controlled study, we compared the behavioral and pharmacological effects of triazolam, meprobamate, and butabarbital in 14 recreational drug users. Placebo and three doses each of triazolam, meprobamate, and butabarbital were administered to each subject in a random order. Objective tests (motor performance, concentration) and subjective response questionnaires measured drug effects. Triazolam, meprobamate, and butabarbital showed comparable negative dose-response slopes on the objective measures. On the basis of these objective data, equivalent doses for the three compounds were determined to be as follows: 0.5 mg triazolam = 2,400 mg meprobamate = 400 mg butabarbital. Subjective effects data on equivalent doses show that butabarbital produced the highest peak score on Cole/ARCI Abuse Potential, ARCI Pentobarbital Chlorpromazine Alcohol Group (PCAG), and "drug strength" scales. Triazolam and butabarbital produced equivalent results on ARCI Morphine Benzedrine Group (MBG), Cole/ARCI Euphoria, and "drug liking" scales. Meprobamate was indistinguishable from placebo on euphoria and abuse potential scales. Behavioral economics analysis indicated a price crossover point two times higher for butabarbital (400 mg) than for any other drug condition. These data indicate a comparative abuse liability of butabarbital > triazolam > or = meprobamate, suggesting that the prescribing restrictions on benzodiazepines had little net benefit on abuse risk in the population and may have increased the risk of overdose morbidity and mortality.
Assuntos
Barbitúricos/farmacologia , Comportamento Aditivo/psicologia , Meprobamato/farmacologia , Triazolam/farmacologia , Adulto , Análise de Variância , Barbitúricos/sangue , Comportamento Aditivo/sangue , Relação Dose-Resposta a Droga , Feminino , Humanos , Masculino , Meprobamato/sangue , Desempenho Psicomotor , Transtornos Relacionados ao Uso de Substâncias/sangue , Transtornos Relacionados ao Uso de Substâncias/psicologia , Triazolam/sangueRESUMO
An adult female ingested a considerable quantity of carisoprodol/acetaminophen tablets, which are not commercially available in Japan, in an attempt to commit suicide. Generally, because of lack of the appreciable ultraviolet absorbance or fluorescence, carisoprodol and its major metabolite meprobamate are determined by gas chromatography or gas chromatography-mass spectrometry. Complicated derivatization is, however, necessary to that methodology. Thus, we investigated the derivatization-free, highly sensitive, and simultaneous determination of carisoprodol, meprobamate, and acetaminophen by means of liquid chromatography-mass spectrometry (LC-MS) with positive electrospray ionization. A semi-micro ODS column was used. Ammonium acetate solution (10mM) and acetonitrile were used as mobile phase at a flow rate of 150 microL/min using gradient elution. MS parameters were as follows: capillary voltage, 3.5 kV; cone voltage, +30 V; extractor voltage, 5 kV; and ion source temperature, 100 degrees C. Urine samples pretreated by Oasis HLB cartridge, or plasma samples deproteinized by adding ice-cold acetonitrile were analyzed by LC-MS. The limits of quantitation for each compound were as follows: 0.50 ng/mL for carisoprodol; 10 ng/mL for acetaminophen; and 1.0 ng/mL for meprobamate. In the present case, carisoprodol and acetaminophen were the only drugs detected. Meprobamate was also found as the metabolite of carisoprodol in both urine and plasma. The plasma levels of carisoprodol, acetaminophen, and meprobamate on arrival were 29.5, 245, and 46.7 microg/mL, respectively. These levels were extremely high compared with therapeutic plasma concentrations. Despite the high plasma concentrations of these drugs, which correspond to fatal levels, the patient survived.